Phase 1 first in man study Evaluating of Pharmacokinetics & Safety of the Tilpisertib Fosmecarbil, an Oral Pro-drug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Tilpisertib fosmecarbil (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- 24 Jan 2025 New trial record